Theriva Biologics Inc
TOVX
查看详细走势图
0.195USD
-0.008-4.14%
收盘 12/24, 13:00（美东）报价延迟15分钟
2.00M总市值
0.09市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-4.14%
5天
+6.05%
1月
-15.76%
6月
-55.59%
今年开始到现在
-88.89%
1年
-88.95%
查看详细走势图
TradingKey Theriva Biologics Inc股票评分
单位: USD 更新时间: 2025-12-24操作建议
Theriva Biologics Inc当前公司基本面数据相对非常健康，增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名212/404位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价7.00。中期看，股价处于下降通道。近一个月，市场表现非常差，但基本面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Theriva Biologics Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
2
位分析师
买入
评级
7.000
目标均价
+3064.56%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Theriva Biologics Inc亮点
亮点风险
Theriva Biologics, Inc. is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. The Company is advancing a new oncolytic adenovirus platform. The Company’s candidates are VCN-01, SYN-004 (ribaxamase) and SYN-020. VCN-01, an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a physical and immunosuppressive barrier to cancer treatment; SYN-004 (ribaxamase) which is designed to degrade certain commonly used IV beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage, thereby limiting overgrowth of pathogenic organisms such as VRE (vancomycin resistant Enterococci), and SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases.
利润高增长
公司净利润处于行业前列，最新年度总收入0.00美元
估值高估
公司最新PE估值0.09，处于3年历史高位
机构减仓
最新机构持股323.11K股，环比减少68.83%
先锋集团持仓
明星投资者先锋集团持仓，最新持仓市值16.38K
活跃度增加
近期活跃度增加，过去20天平均换手率-0.45
Theriva Biologics Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Theriva Biologics Inc简介
Theriva Biologics, Inc. is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. The Company is advancing a new oncolytic adenovirus platform. The Company’s candidates are VCN-01, SYN-004 (ribaxamase) and SYN-020. VCN-01, an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a physical and immunosuppressive barrier to cancer treatment; SYN-004 (ribaxamase) which is designed to degrade certain commonly used IV beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage, thereby limiting overgrowth of pathogenic organisms such as VRE (vancomycin resistant Enterococci), and SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases.
公司代码TOVX
公司Theriva Biologics Inc
CEOShallcross (Steven A)
网址https://therivabio.com/
常见问题
Theriva Biologics Inc(TOVX)的当前股价是多少？
Theriva Biologics Inc(TOVX)的当前股价是 0.195。
Theriva Biologics Inc的股票代码是什么？
Theriva Biologics Inc的股票代码是TOVX。
Theriva Biologics Inc股票的52周最高点是多少？
Theriva Biologics Inc股票的52周最高点是2.080。
Theriva Biologics Inc股票的52周最低点是多少？
Theriva Biologics Inc股票的52周最低点是0.165。
Theriva Biologics Inc的市值是多少？
Theriva Biologics Inc的市值是2.00M。
Theriva Biologics Inc的净利润是多少？
Theriva Biologics Inc的净利润为-25.65M。
现在Theriva Biologics Inc(TOVX)的股票是买入、持有还是卖出？
根据分析师评级，Theriva Biologics Inc(TOVX)的总体评级为买入，目标价格为7.000。
Theriva Biologics Inc(TOVX)股票的每股收益（EPS TTM）是多少
Theriva Biologics Inc(TOVX)股票的每股收益（EPS TTM）是2.062。
相关品种
